Safety of brigatinib following alectinib-induced-pneumonitis: Case report

Safety of brigatinib following alectinib-induced-pneumonitis: Case report

Anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK TKIs) show robust efficacy and has revolutionized the treatment of NSCLC patients harboring an ALK-rearrangement. Side effects, sometimes even serious such as pneumonitis, can occur with ALK TKIs.We report a case of a patient with ALK positi...

Full description

Saved in:
Bibliographic Details
Main Authors: Blerina Resuli, Heidi Galarza, Laura Elsner, Diego Kauffmann-Guerrero, Jürgen Behr, Amanda Tufman
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Respiratory Medicine Case Reports
Subjects:
Alectinib
Brigatinib
NSCLC
Pneumonitis
Case report
Online Access:http://www.sciencedirect.com/science/article/pii/S2213007124001837
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items